Results 11 to 20 of about 7,663 (213)

Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression [PDF]

Journal of Affective Disorders Reports
Background: Esketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce.
Abel (K.A.J.) Busz, Emma (E.J.) Schmidt, Rob (R.H.S.) van den Brink, Karen (K.) Foeken, Marasha (M.) de Jong, Joost (J.B.C.) Mertens, Martijn (M.S.) van Noorden, Etienne (E.J.F.L.) Olivier, Koen (K.R.J.) Schruers, Sara (S.I.J.) Schutters, Joris (J.) van Son, Wessel (W.J.) Strootker, Harry (H.C.P.) Venema, Dieuwertje (D.A.) de Waardt, Jasper (J.B.) Zantvoord, Danielle (D.) Cath, Henricus (H.G.) Ruhe   +16 more
doaj   +3 more sources

Effect of esketamine on hypotension in women with preoperative anxiety undergoing elective cesarean section: a randomized, double-blind, controlled trial [PDF]

Scientific Reports
To investigate the effect of low-doses esketamine on spinal anesthesia-induced hypotension in women with preoperative anxiety undergoing elective cesarean section, the randomized controlled trial enrolled 120 women aged 18–35 years who preoperative State-
Yu Qi, Meiyan Zhou, Yaqi Dong, Wenting Zheng, Qinyu Jiang, Yanyu Li, Xinghe Wang, Jia Sun, Hai Zhou, Zhengquan Hu, Liwei Wang   +10 more
doaj   +3 more sources

Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study [PDF]

Pharmaceuticals
Background: Esketamine is a rapidly acting antidepressant with robust efficacy in treatment-resistant depression (TRD). Diminishing therapeutic effects and attenuated side effects have been reported after long-term use.
Jolien K. E. Veraart, Cornelis F. Vos, Nieko C. Punt, Dylan Visser, Mireille A. Wessels, Sanne Y. Smith-Apeldoorn, Jeanine Kamphuis, Robert A. Schoevers, Daan J. Touw   +8 more
doaj   +3 more sources

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment [PDF]

European Journal of Pharmacology
Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression.
Jolien K.E. Veraart, Sanne Y. Smith-Apeldoorn, Jeanine Kamphuis, Daan J. Touw, Robert A. Schoevers   +4 more
openaire   +5 more sources

Moderate-to-deep sedation technique, using propofol and ketamine, allowing synchronised breathing for magnetic resonance high-intensity focused ultrasound (MR-HIFU) treatment for uterine fibroids: a pilot study [PDF]

, 2017
BACKGROUND: Magnetic resonance high-intensity focused ultrasound (MR-HIFU) treatment for uterine fibroids is rapidly gaining popularity as a treatment modality.
F. M. Knuttel, Hermanus H. B. Vaessen, J. M. Dieleman, J. M. M. van Breugel, J. T. A. Knape, M. A. A. J. van den Bosch, M. E. Ikink   +6 more
core   +10 more sources

Exploring the role of esketamine in alleviating depressive symptoms in mice via the PGC-1α/irisin/ERK1/2 signaling pathway

Scientific Reports, 2023
Esketamine provides an immediate and noticeable antidepressant effect, although the underlying molecular processes are yet unclear. Irisin induced by aerobic exercise has been implicated in the alleviation of depressive symptoms, whether irisin ...
Na Hu, Xuemei Chen, Chengchuan Chen, Xing Liu, Peng Yi, Tianhao Xu, Jing Jia, Jianguo Feng, Chunxiang Zhang, Xiaobin Wang   +9 more
doaj   +1 more source

The antidepressant effect and safety of non-intranasal esketamine:A systematic review [PDF]

, 2022
BACKGROUND: The introduction of esketamine into the field of psychiatry comes on the heels of excitement from studies on racemic ketamine. While the intranasal route has been the most studied to date, other modes of administration of esketamine may also ...
Aan Het Rot, Marije, Kamphuis, Jeanine, Schoevers, Robert A, Smith-Apeldoorn, Sanne Y, Veraart, Jolien Ke, Vischjager, Maurice   +5 more
core   +1 more source

Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial

BMC Anesthesiology, 2022
Background Esketamine is an antagonist of the N-methyl-D-aspartate receptor (NMDA receptor) that is widely used for multimodal analgesia. In addition to analgesia, sedation is another important effect of esketamine.
Cao Zhang, Jiangqin He, Qinye Shi, Fangping Bao, Jianhong Xu   +4 more
doaj   +1 more source

Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg depression rating scale, the gold standard clinician rating scale : a meta-analysis of randomised placebo-controlled trials [PDF]

, 2020
It has been claimed that efficacy estimates based on the Hamilton Depression Rating-Scale (HDRS) underestimate antidepressants true treatment effects due to the instrument's poor psychometric properties.
Hengartner, Michael Pascal, Jakobsen, Janus C., Plöderl, Martin, Sørensen, Anders   +3 more
core   +2 more sources

Esketamin [PDF]

pharma-kritik, 2021
In Form eines Nasensprays (Spravato®) ist das S-Enantiomer von Ketamin zur Behandlung einer «therapieresistenten» Depression zugelassen. Hinsichtlich der psychischen Auswirkungen teilt diese Form die Eigenschaften von Ketamin.
openaire   +1 more source